GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anatara Lifesciences Ltd (ASX:ANR) » Definitions » EV-to-FCF

Anatara Lifesciences (ASX:ANR) EV-to-FCF : -4.25 (As of May. 13, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Anatara Lifesciences EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Anatara Lifesciences's Enterprise Value is A$6.55 Mil. Anatara Lifesciences's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was A$-1.54 Mil. Therefore, Anatara Lifesciences's EV-to-FCF for today is -4.25.

The historical rank and industry rank for Anatara Lifesciences's EV-to-FCF or its related term are showing as below:

ASX:ANR' s EV-to-FCF Range Over the Past 10 Years
Min: -182.92   Med: -1.74   Max: 1.76
Current: -4.25

During the past 9 years, the highest EV-to-FCF of Anatara Lifesciences was 1.76. The lowest was -182.92. And the median was -1.74.

ASX:ANR's EV-to-FCF is ranked worse than
100% of 390 companies
in the Biotechnology industry
Industry Median: 6.365 vs ASX:ANR: -4.25

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-13), Anatara Lifesciences's stock price is A$0.041. Anatara Lifesciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.013. Therefore, Anatara Lifesciences's PE Ratio for today is At Loss.


Anatara Lifesciences EV-to-FCF Historical Data

The historical data trend for Anatara Lifesciences's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anatara Lifesciences EV-to-FCF Chart

Anatara Lifesciences Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only -2.96 -1.39 -3.59 -1.26 -1.31

Anatara Lifesciences Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -1.26 - -1.31 -

Competitive Comparison of Anatara Lifesciences's EV-to-FCF

For the Biotechnology subindustry, Anatara Lifesciences's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anatara Lifesciences's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anatara Lifesciences's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Anatara Lifesciences's EV-to-FCF falls into.



Anatara Lifesciences EV-to-FCF Calculation

Anatara Lifesciences's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=6.546/-1.54
=-4.25

Anatara Lifesciences's current Enterprise Value is A$6.55 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Anatara Lifesciences's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was A$-1.54 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Anatara Lifesciences  (ASX:ANR) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Anatara Lifesciences's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.041/-0.013
=At Loss

Anatara Lifesciences's share price for today is A$0.041.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Anatara Lifesciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.013.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Anatara Lifesciences EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Anatara Lifesciences's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Anatara Lifesciences (ASX:ANR) Business Description

Traded in Other Exchanges
N/A
Address
c/- Perks, 81 Flinders Street, Level 8, Adelaide, SA, AUS, 5000
Anatara Lifesciences Ltd is developing non-antibiotic oral solutions for gastrointestinal diseases in animals and humans. Its products include the Gastrointestinal ReProgramming dietary supplement (GaRP) for humans and Detach for animals. It generates its income from license revenue.

Anatara Lifesciences (ASX:ANR) Headlines

No Headlines